No clear relationship has been reported in MPS I and II between exposure to higher ADAs and risk of adverse events or suboptimal clinical outcome, except in one case of MPSI whose ADAs inhibited cellular uptake of enzyme by more than 80% [44,196,199]. Here, AGPS is linked to mucopolysaccharidosis type 1.